Philippe Desfontaines

Philippe Desfontaines

Auto-generated profile, based on publicly available information

Philippe Desfontaines

Department of Neurology, Stroke Unit, CHC Groupe Santé, Liège, Belgium (P.D.).

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Stroke
Verified
Journal Article
Closed access
AWAnke Wouters
Anke Wouters
JDJelle Demeestere
Jelle Demeestere
JRJean-Benoît Rossel
Jean-Benoît Rossel
ADAnnemie Devroye
Annemie Devroye
PDPhilippe Desfontaines
Philippe Desfontaines
FIfor the ELAN Investigators
for the ELAN Investigators
BACKGROUND: Early initiation of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation and acute ischemic stroke is beneficial and safe. Whether prior acute reperfusion therapy modifies the treatment effect of early versus late DOAC initiation is unknown. METHODS: For this post hoc analysis of the multicenter, randomized controlled ELAN trial (Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation), all participants with data concerning reperfusion treatment were included. The primary outcome was the composite outcome of recurrent ischemic stroke, symptomatic intracranial hemorrhage, major extracranial bleeding, systemic embolism, or vascular death within 30 days. Patients were divided into 4 groups based on prior reperfusion therapy: no treatment, intravenous thrombolysis (IVT), endovascular treatment (EVT), or IVT combined with EVT. We performed logistic regression adjusted for age, hypertension, infarct location/size, pre-modified Rankin Scale, NIHSS, and hemorrhagic transformation, including the interaction term between treatment groups (early versus late DOAC) and reperfusion strategy. RESULTS: We included 1973 of 2013 (98%) patients of the ELAN trial population, with a median age of 77 (71–84) years and of whom 899 (46%) were female. Of them, 1015 (51%) underwent no prior reperfusion treatment, 519 (26%) IVT, 190 (10%) EVT, and 249 (13%) IVT+EVT. We did not identify an interaction for any of the outcome events between prior reperfusion therapy and timing of DOAC initiation. Rates were numerically lower in the early DOAC-initiated group for the following: no reperfusion therapy, 17 (3.3%) versus 24 (4.8%; adjusted odds ratio, 0.69 [95% CI, 0.36–1.28]); EVT, 1 (1.2%) versus 7 (6.4%; adjusted odds ratio, 0.25 [95% CI, 0.03–1.21]); and EVT+IVT, 3 (2.4%) versus 4 (3.3%; adjusted odds ratio, 0.76 [95% CI, 0.17–3.23]). In patients who had received IVT, the rates were 3% (n=8) in the early group versus 2% (n=5) in the late group (adjusted odds ratio, 1.52 [95% CI, 0.52–4.84]). CONCLUSIONS: Prior reperfusion therapy does not modify the effect of early versus late DOAC initiation on clinical outcomes in patients with atrial fibrillation and acute ischemic stroke. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03148457.

14 January 2025 in Neurology
Verified
Journal Article
Closed access
MKMarkus Kneihsl
Markus Kneihsl
AHArsany Hakim
Arsany Hakim
MGMartina B. Goeldlin
Martina B. Goeldlin
TMThomas R. Meinel
Thomas R. Meinel
MBMattia Branca
Mattia Branca
FIfor the ELAN investigators
for the ELAN investigators
Covert brain infarcts (CBIs) in patients with first-ever ischemic stroke (IS) and atrial fibrillation (AF) are associated with an increased risk of stroke recurrence. We aimed to assess whether CBIs modify the treatment effect of early vs late initiation of direct oral anticoagulants (DOACs) in patients with IS and AF. We conducted a post hoc analysis of the international, multicenter, randomized-controlled ELAN trial, which compared early (48 hours for minor, 3-4 days for moderate, 12-14 days for major stroke) initiation of DOACs in patients with IS and AF. The primary outcome was a composite of recurrent IS, symptomatic intracranial hemorrhage (sICH), major extracranial bleeding, systemic embolism, or vascular death within 30 days after stroke; secondary outcomes were the individual components. We estimated outcomes based on the presence of CBIs (any CBI vs no CBI) on prerandomization imaging (core-lab rating) using adjusted risk differences (aRDs) between treatment arms. Point estimates and 95% CIs are presented without reporting p values. Of the 1,694 participants with first-ever IS included (median age: 77 years, 45.9% female), 678 (40.0%) had CBI. The imaging core-lab interrater reliability for the presence of CBI was 0.87 (0.81-0.94). The primary outcome occurred in 8 (2.3%; recurrent IS: 3/342) of 342 participants with CBI assigned to the early treatment arm vs 20 (6.0%; recurrent IS: 12/336) of 336 assigned to the late treatment arm (aRD: -3.6%, 95% CI -6.6 to -0.6) (p for interaction: 0.063). With early DOAC treatment, IS recurrence risk was lower in participants with CBI (aRD: -2.7%, 95% CI -5.0 to -0.4), but not in participants without CBI (aRD: -0.4, 95% CI -2.1 to 1.2). No sICH was observed in the early treatment group. The presence of CBI may indicate a subgroup of patients with first-ever IS and AF who particularly benefits from early DOAC initiation to prevent ischemic event recurrence, without increasing harm. Our findings should be considered in clinical decision making regarding timely DOAC treatment in patients with stroke and AF. This study provides Class II evidence that in patients with covert brain infarcts, atrial fibrillation, and first-ever ischemic stroke, early (vs late) initiation of DOACs is associated with lower risk of recurrent stroke with no increase in harm. URL: clinicaltrials.gov/study/NCT03148457; Unique identifier: NCT03148457; submitted: April 7, 2017; first patient enrolled: November 6, 2017.

22 October 2026 in Stroke
Verified
Journal Article
Open access
LMLouise Maes
Louise Maes
AWAnke Wouters
Anke Wouters
JPJo P. Peluso
Jo P. Peluso
JDJelle Demeestere
Jelle Demeestere
PDPhilippe Desfontaines
Philippe Desfontaines
RLRobin Lemmens
Robin Lemmens
BACKGROUND: The carotid Plaque Reporting and Data System (Plaque-RADS) provides a standardized framework for evaluating plaque morphology, but prospective validation remains limited. We investigated the association between computed tomography angiography-based Plaque-RADS categories and subsequent ischemic events in patients with noncardioembolic stroke/transient ischemic attack, from a completed clinical trial of colchicine. Second, we assessed whether the effect of colchicine differed by Plaque-RADS risk classification. METHODS: We conducted a posthoc observational cohort analysis of 517 participants in the CONVINCE trial (Colchicine for Prevention of Vascular Inflammation in Non-CardioEmbolic Stroke) from 13 European sites. Associations between Plaque-RADS and recurrent ipsilateral stroke, any stroke/transient ischemic attack, and major adverse cardiovascular events were assessed using multivariable Cox proportional hazards models. Plaque-RADS was analyzed as both dichotomized (<3 versus ≥3) and ordinal (per 1-point increase) variables. Treatment effects were assessed by Plaque-RADS classification using interaction and stratified analyses. RESULTS: A total of 510 patients (median age, 67.0 years; 72.2% male) with 966 internal carotid arteries were included. Among 321 internal carotid arteries ipsilateral to the index ischemic stroke, 12 recurrent ipsilateral strokes, 32 any strokes/transient ischemic attacks, and 37 major adverse cardiovascular events occurred over a median 35.7-month follow-up. Plaque-RADS ≥3 (n=140) was independently associated with recurrent ipsilateral stroke (adjusted hazard ratio, 7.80 [95% CI, 1.55–39.30]; P =0.01), any stroke/transient ischemic attack (adjusted hazard ratio, 3.94 [95% CI, 1.68–9.24]; P <0.01), and major adverse cardiovascular events (adjusted hazard ratio, 2.52 [95% CI, 1.19–5.34]; P =0.02) after adjustment for age, sex and cardiovascular risk factors. A significant interaction with colchicine treatment was observed for major adverse cardiovascular events ( P =0.047), with greater benefit among patients with Plaque-RADS scores ≥3 (hazard ratio, 0.35 [95% CI, 0.15–0.82]). CONCLUSIONS: In internal carotid arteries ipsilateral to the index ischemic stroke, computed tomography angiography-based carotid Plaque-RADS was associated with recurrent ischemic stroke and cardiovascular events. Importantly, treatment effects of colchicine varied across Plaque-RADS classification (<3 versus ≥3), suggesting that plaque vulnerability assessment may help refine patient selection for anti-inflammatory therapy beyond stenosis-based classification. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02898610.